2022
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.
Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.Peer-Reviewed Original ResearchTriple-negative breast cancerComprehensive genomic profilingMetastatic breast cancerBreast cancerClinical trialsPathology reportsMutational profileHER2- metastatic breast cancerConsecutive breast cancersAnti-estrogen therapyNegative breast cancerPD-L1 IHCPotential therapeutic implicationsHigh rateEndocrine therapyEstrogen therapyPatient ageFoundation MedicineKRAS alterationsRare subtypeHER2 expressionClinical behaviorReceptor phenotypeBreast carcinomaTreatment strategies
2015
Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue
Lester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.Peer-Reviewed Original ResearchBreast cancer survivorsAtrophic vaginitisCancer survivorsEndocrine therapySelective estrogen receptor modulatorsSystemic estrogen therapyPatient-reported symptomsEstrogen receptor modulatorsVariety of symptomsQuality of lifeVaginal moistureEstrogen therapyLifestyle modificationLocal estrogenTopical estrogenVaginal drynessGynecological examinationSurvivorship issuesGenital skinOvarian failureVaginal dischargeSystematic therapyAromatase inhibitorsReceptor modulatorsBreast cancer